Registered title, quoted from ClinicalTrials.gov
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06996132, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 65 years; sex: all
Registered eligibility fields
Biopsy-proven residual disease following initial therapy.
Inclusion criterion 10
≥2 prior lines of therapy (including both anti-CD20 monoclonal antibody and anthracycline-based chemotherapy) with documented progression following last treatment; OR
Inclusion criterion 3
Persistent metabolic activity (Deauville 5) on PET-CT after 2 cycles of first-line immunochemotherapy; OR
Inclusion criterion 9
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Inclusion criterion 12
Absolute neutrophil count (ANC) ≥1×10⁹/L,
Inclusion criterion 14
Platelet count (PLT) ≥75×10⁹/L.
Inclusion criterion 15
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN);
Inclusion criterion 17
Total bilirubin (TBIL) ≤1.5×ULN (unless due to Gilbert's syndrome or non-hepatic causes);
Inclusion criterion 18
Serum creatinine (Cr) ≤2×ULN OR creatinine clearance ≥40 mL/min.
Inclusion criterion 19
Active HBV or HCV infection, defined as HBV-DNA or HCV-RNA levels above the upper limit of detection.
Exclusion criterion 3
HIV infection;
Exclusion criterion 7
Pregnancy or lactation;
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06996132, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients with relapsed/refractory aggressive B-cell lymphoma, including the following subtypes: diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), or transformed large B-cell lymphoma.
- Relapsed or refractory disease, meeting criteria for one of the following cohorts:
Cohort 1 (Relapsed/Refractory Disease):
- ≥2 prior lines of therapy (including both anti-CD20 monoclonal antibody and anthracycline-based chemotherapy) with documented progression following last treatment; OR
- Failure of first-line immunochemotherapy (containing anti-CD20 antibody and anthracycline) defined by any of:
- Relapse/progression within 12 months of treatment completion; OR
- Progressive disease during first-line therapy; OR
- Stable disease as best response after 4 cycles; OR
- Partial response as best response after 6 cycles.
Cohort 2 (Early Treatment Failure):
- Persistent metabolic activity (Deauville 5) on PET-CT after 2 cycles of first-line immunochemotherapy; OR
- Biopsy-proven residual disease following initial therapy.
- Age ≥18 years and ≤65 years.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
- Hematologic parameters at screening must meet the following (unless due to bone marrow involvement):
- Absolute neutrophil count (ANC) ≥1×10⁹/L,
- Platelet count (PLT) ≥75×10⁹/L.
- Biochemical parameters at screening must meet the following:
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN);
- Total bilirubin (TBIL) ≤1.5×ULN (unless due to Gilbert's syndrome or non-hepatic causes);
- Serum creatinine (Cr) ≤2×ULN OR creatinine clearance ≥40 mL/min.
- Left ventricular ejection fraction (LVEF) within institutional normal range by echocardiography.
- Baseline oxygen saturation >92% on room air.
- Life expectancy ≥3 months as assessed by the investigator.
Exclusion Criteria:
- Confirmed primary central nervous system lymphoma;
- Prior autologous or allogeneic hematopoietic stem cell transplantation;
- Active HBV or HCV infection, defined as HBV-DNA or HCV-RNA levels above the upper limit of detection.
- Uncontrolled comorbidities include infectious diseases, cardiovascular/cerebrovascular disorders, coagulopathies, and connective tissue diseases.
- History of epilepsy or other central nervous system disorders;
- Pregnancy or lactation;
- HIV infection;
- History of other malignancies unless:
- Disease-free for ≥5 years, or
- Previously cured of the following:
- Non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma, or related localized cutaneous malignancies)
- Carcinoma in situ of cervix
- Other conditions deemed ineligible by investigators.
Quoted from ClinicalTrials.gov, NCT06996132, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06996132, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.